文献速递皮肤肿瘤

实体器官移植后黑色素瘤的发病率、分期与生存:加拿大安大略省基于人群的队列研究

Melanoma incidence, stage, and survival after solid organ transplant: A population-based cohort study in Ontario, Canada.
PubMed 文献 · J Am Acad Dermatol · 2020-02-25

该研究利用加拿大安大略省关联行政数据库,纳入1991至2012年首次接受实体器官移植的成人并随访至2013年12月,发现移植受者黑色素瘤风险升高(标化发病比2.29,95%CI 2.07-2.49),更易诊断为期II-IV期(调整比值比4.29,95%CI 2.04-9.00),且黑色素瘤特异性死亡风险增加(调整风险比1.93,95%CI 1.03-3.63)。

要点

  • 移植受者黑色素瘤标化发病比为2.29,风险显著高于普通人群。
  • 移植受者更易在II-IV期确诊,调整比值比4.29。
  • 即使早期黑色素瘤(T1/T2),移植受者全因死亡风险仍增加(调整风险比2.18)。

核心结论

  • 实体器官移植后黑色素瘤更常诊断于较晚分期,且导致死亡率增加,即使对于早期肿瘤也是如此。

研究设计与样本

  • 基于人群的回顾性观察性研究,使用关联行政数据库,纳入1991至2012年首次接受实体器官移植的成人,随访至2013年12月。

主要发现

  • 移植受者黑色素瘤风险增加(标化发病比2.29;95%CI 2.07-2.49),更易诊断为期II-IV期(调整比值比4.29;95%CI 2.04-9.00)。
  • 移植受者黑色素瘤特异性死亡风险高于非移植人群(调整风险比1.93;95%CI 1.03-3.63)。
  • 移植受者中,黑色素瘤后全因死亡风险增加:T1/T2期调整风险比2.18(95%CI 1.13-4.21);T3/T4期调整风险比4.07(95%CI 2.36-7.04);III/IV期调整风险比7.92(95%CI 3.76-16.70)。

临床怎么用

  • 对实体器官移植受者应加强黑色素瘤筛查和随访,警惕晚期诊断及早期肿瘤的死亡风险。

局限性

  • 数据库未包含免疫抑制药物数据;黑色素瘤转移的确认依赖病理报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Risk of melanoma is increased with potentially worse outcomes after solid organ transplant. OBJECTIVE: To estimate the incidence, stage, and survival in transplant recipients with melanoma. METHODS: Population-based, retrospective, observational study using linked administrative databases. Adults receiving their first solid organ transplant from 1991 through 2012 were followed to December 2013. RESULTS: We identified 51 transplant recipients with melanoma, 11 369 recipients without melanoma, and 255 matched patients with melanoma from the nontransplant population. Transplant recipients were at increased risk of melanoma (standardized incidence ratio, 2.29; 95% confidence interval [CI], 2.07-2.49) and more likely to be diagnosed at stages II through IV (adjusted odds ratio, 4.29; 95% CI, 2.04-9.00) compared with the nontransplant population. Melanoma-specific mortality was increased in transplant recipients compared with the nontransplant population (adjusted hazard ratio, 1.93; 95% CI, 1.03-3.63). Among transplant recipients, all-cause mortality was increased after melanoma compared with those without melanoma (stage T1/T2: adjusted hazard ratio, 2.18; 95% CI, 1.13-4.21; T3/T4: adjusted hazard ratio, 4.07; 95% CI, 2.36-7.04; III/IV: adjusted hazard ratio, 7.92; 95% CI, 3.76-16.70). LIMITATIONS: The databases did not contain data on immunosuppressive drugs; ascertainment of melanoma metastasis relied on pathology reports. CONCLUSION: Melanoma after solid organ transplant is more often diagnosed at a later stage and leads to increased mortality, even for early-stage tumors.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Park CK, Dahlke EJ, Fung K, et al. Melanoma incidence, stage, and survival after solid organ transplant: A population-based cohort study in Ontario, Canada. J Am Acad Dermatol. 2020. PMID: 32111554. doi:10.1016/j.jaad.2019.09.072

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。